The approval was based on data from 3 phase 3 trials which compared the efficacy of different dosing regimens of ...

Targeted prevention strategies and increased public awareness and vaccination coverage are needed to reduce the significant ...

The concurrent administration of bivalent mRNA COVID-19 boosters and influenza vaccines should be considered as a strategy to potentiate neutralizing antibody responses against SARS-CoV-2. Concurrent ...

Compared to hospitalization for COVID-19, hospitalization for influenza was associated with a higher risk for neurologic disorders the year after infection. Patients hospitalized for influenza vs ...

Pneumococcal vaccination did not affect length of stay in patients age 65 years and older who were hospitalized in South Korea for community-acquired pneumonia. Prior pneumococcal vaccination was ...

Obstructive sleep apnea was linked to a higher risk for COVID-19 positivity in veterans studied and greater use of noninvasive mechanical ventilation in those hospitalized with COVID-19. Some COVID-19 ...

Higher intravenous ketamine doses do not outperform standard doses for treatment resistant depression. Intravenous (IV) ketamine for treatment resistant depression is effective at lower doses of 0.2 ...

Increased protection against COVID-19-related hospitalization was observed among immunocompromised adults who received the updated 2023-2024 COVID-19 vaccine. The updated 2023-2024 COVID-19 vaccine ...

In pediatric patients hospitalized with severe acute COVID-19, those with immunocompromising conditions had worse outcomes despite having similar disease severity relative to non-immunocompromised ...

High-dose influenza vaccine is associated with a more robust humoral response in patients with heart failure and history of myocardial infarction. Among patients with heart failure (HF) or previous ...

SARS-CoV-2 antibody levels may be a correlate for immunity against COVID-19 infection and help determine the optimal timing of booster receipt. Serologic testing may allow individual-level assessment ...

Ensifentrine for Maintenance Treatment of COPD PDUFA date: June 26, 2024 Ensifentrine is a first-in-class, dual phosphodiesterase 3 and 4 inhibitor with combined bronchodilator and anti-inflammatory ...